Grape King Bio Ltd (1707.TW)
TWD 151.0
(0.0%)
TWD 151.0
(0.0%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 136.36 Million TWD | 23.06% |
| 2022 | 110.8 Million TWD | -48.81% |
| 2021 | 216.45 Million TWD | -85.5% |
| 2020 | 1.49 Billion TWD | 58.62% |
| 2019 | 941.27 Million TWD | 221.48% |
| 2018 | 292.79 Million TWD | -43.55% |
| 2017 | 518.67 Million TWD | -53.38% |
| 2016 | 1.11 Billion TWD | -53.9% |
| 2015 | 2.41 Billion TWD | 0.0% |
| 2014 | - TWD | 0.0% |
| 2013 | - TWD | 0.0% |
| 2012 | - TWD | 0.0% |
| 2011 | - TWD | 0.0% |
| 2010 | - TWD | 0.0% |
| 2009 | - TWD | -100.0% |
| 2008 | 39.19 Million TWD | 21.18% |
| 2007 | 32.34 Million TWD | 10.6% |
| 2006 | 29.24 Million TWD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 128.98 Million TWD | 0.0% |
| 2024 Q2 | 125.87 Million TWD | 0.0% |
| 2023 Q1 | 103.31 Million TWD | -6.77% |
| 2023 Q3 | 147.79 Million TWD | -7.11% |
| 2023 Q2 | 159.11 Million TWD | 54.01% |
| 2023 FY | 136.36 Million TWD | 23.06% |
| 2023 Q4 | 136.36 Million TWD | -7.74% |
| 2022 FY | 110.8 Million TWD | -48.81% |
| 2022 Q1 | 120.96 Million TWD | -44.11% |
| 2022 Q4 | 110.8 Million TWD | -17.27% |
| 2022 Q3 | 133.93 Million TWD | -5.29% |
| 2022 Q2 | 141.41 Million TWD | 16.9% |
| 2021 Q1 | 314.76 Million TWD | -78.92% |
| 2021 FY | 216.45 Million TWD | -85.5% |
| 2021 Q3 | 315.69 Million TWD | 3.5% |
| 2021 Q4 | 216.45 Million TWD | -31.43% |
| 2021 Q2 | 305.03 Million TWD | -3.09% |
| 2020 FY | 1.49 Billion TWD | 58.62% |
| 2020 Q1 | 962.68 Million TWD | 2.27% |
| 2020 Q2 | 1.28 Billion TWD | 33.26% |
| 2020 Q3 | 1.51 Billion TWD | 17.88% |
| 2020 Q4 | 1.49 Billion TWD | -1.27% |
| 2019 Q1 | 440.51 Million TWD | 50.45% |
| 2019 Q2 | 524.02 Million TWD | 18.96% |
| 2019 Q3 | 1.11 Billion TWD | 112.01% |
| 2019 Q4 | 941.27 Million TWD | -15.27% |
| 2019 FY | 941.27 Million TWD | 221.48% |
| 2018 FY | 292.79 Million TWD | -43.55% |
| 2018 Q4 | 292.79 Million TWD | -40.72% |
| 2018 Q3 | 493.9 Million TWD | -1.61% |
| 2018 Q2 | 501.97 Million TWD | -1.7% |
| 2018 Q1 | 510.66 Million TWD | -1.54% |
| 2017 Q1 | 1.09 Billion TWD | -1.22% |
| 2017 FY | 518.67 Million TWD | -53.38% |
| 2017 Q4 | 518.67 Million TWD | -27.27% |
| 2017 Q2 | 991.77 Million TWD | -9.75% |
| 2017 Q3 | 713.17 Million TWD | -28.09% |
| 2016 Q1 | 2.2 Billion TWD | -8.69% |
| 2016 FY | 1.11 Billion TWD | -53.9% |
| 2016 Q3 | 1.32 Billion TWD | -36.45% |
| 2016 Q4 | 1.11 Billion TWD | -16.32% |
| 2016 Q2 | 2.09 Billion TWD | -5.04% |
| 2015 Q3 | 2.52 Billion TWD | 41.67% |
| 2015 FY | 2.41 Billion TWD | 0.0% |
| 2015 Q4 | 2.41 Billion TWD | -4.55% |
| 2015 Q2 | 1.78 Billion TWD | 0.0% |
| 2015 Q1 | - TWD | 0.0% |
| 2014 Q4 | - TWD | 0.0% |
| 2014 Q2 | - TWD | 0.0% |
| 2014 Q1 | - TWD | 0.0% |
| 2014 FY | - TWD | 0.0% |
| 2014 Q3 | - TWD | 0.0% |
| 2013 Q4 | - TWD | 0.0% |
| 2013 Q3 | - TWD | 0.0% |
| 2013 Q2 | - TWD | 0.0% |
| 2013 Q1 | - TWD | 0.0% |
| 2013 FY | - TWD | 0.0% |
| 2012 Q1 | - TWD | 0.0% |
| 2012 FY | - TWD | 0.0% |
| 2012 Q2 | - TWD | 0.0% |
| 2012 Q3 | - TWD | 0.0% |
| 2012 Q4 | - TWD | 0.0% |
| 2011 Q2 | - TWD | 0.0% |
| 2011 FY | - TWD | 0.0% |
| 2011 Q1 | - TWD | 0.0% |
| 2011 Q4 | - TWD | 0.0% |
| 2011 Q3 | - TWD | 0.0% |
| 2010 FY | - TWD | 0.0% |
| 2010 Q4 | - TWD | 0.0% |
| 2009 FY | - TWD | -100.0% |
| 2008 FY | 39.19 Million TWD | 21.18% |
| 2007 FY | 32.34 Million TWD | 10.6% |
| 2006 FY | 29.24 Million TWD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Standard Chem & Pharm CO., LTD. | 222.97 Million TWD | 38.845% |
| Maywufa Company Ltd. | 438.97 Million TWD | 68.937% |
| ScinoPharm Taiwan, Ltd. | 570.23 Million TWD | 76.087% |
| Lotus Pharmaceutical Co., Ltd. | 9.51 Billion TWD | 98.568% |
| LIWANLI Innovation Co., Ltd. | 361 Thousand TWD | -37672.853% |
| YungShin Global Holding Corporation | 241.99 Million TWD | 43.652% |
| PhytoHealth Corporation | 17.46 Million TWD | -680.985% |
| SCI Pharmtech, Inc. | 845.52 Million TWD | 83.873% |
| Formosa Laboratories, Inc. | 2.03 Billion TWD | 93.309% |
| PharmaEssentia Corporation | 954.99 Million TWD | 85.721% |
| Bora Pharmaceuticals Co., LTD. | 3.48 Billion TWD | 96.089% |